× We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click our cookies policy for information on how to change your cookie settings.


× Important note: This Web site presents preliminary results. We are working to complete the biocuration as soon as possible.

meta|Evidence - COVID-19

Live meta-analysis and evidence synthesis of potential therapies for COVID19

  Summary of results of all meta-analysis  
tutorial video
En     Fr

Our approach


adjuvant therapies

anticoagulant 2

Bivalirudin

colchicine 1

face mask

febuxostat

hydrogen-oxygen nebulizer

hyperbaric oxygen

nintedanib

pulmonary rehabilitation

thalidomide

vitamin C

anti-inflammatoty and immuno-therapy

acalabrutinib

anti-inflammatory therapies 1

IFX-1

naproxen, ibuprofen

non-steroidal anti-inflammatory drugs

sodium aescinate

Apilimod

corticosteroids 8

ciclesonide

dexamethasone 2

Hydrocortisone 2

inhaled steroids

low-dose corticosteroids

methylprednisolone 2

imatinib

Immunostimulants drugs

anti-PD-1 antibody

CD24Fc

convalescent plasma treatment 11

immunoglobulin therapy

emapalumab

inactivated mycobacterium vaccine

Interleukin-2

neutralizing antibody

rhG-CSF

vaccines

BCG vaccination

Immunosuppressants drugs

anakinra 1

baricitinib

eculizumab

interleukin-6 inhibitor

clazakizumab

sarilumab 3

sarilumab azithromycin hydroxychloroquine

sarilumab high dose (400mg) 1

sarilumab low dose (200mg) 1

siltuximab

tocilizumab 18

jakotinib

lenzilumab

ruxolitinib

tacrolimus

tetrandrine

leflunomide

pirfenidone

Polyinosinic-Polycytidylic Acid

sargramostim

thymosin

antiviral and associated therapy

ASC09/ritonavir

azithromycin 2

azvudine

baloxavir marboxil

bromhexine

carrimycin

chloroquine and derivatives 6

chloroquine 2

hydroxychloroquine 30

danoprevir / ritonavir

darunavir cobicistat

darunavir/cobicistat plus chloroquine

favipiravir 1

fluvoxamine

hydroxychloroquine plus macrolides 7

interferon 1

SNG001 inhaled interferon beta 1

ivermectin

leronlimab

lopinavir / ritonavir plus ribavirin

lopinavir/ritonavir 4

lopinavir/ritonavir plus interferon ß-1a

lopinavir/ritonavir, ribavirin and interferon beta-1b

meplazumab

oseltamivir plus chloroquin

remdesevir 6

Renin-angiotensin-system-acting agents 7

angiotensin receptor blockers (ARBs)

angiotensin-(1-7)

discontinuation of ACEI/ARB 1

RAS blocker withdrawal

rhACE2

ritonavir

tranexamic acid

triazavirin

umifenovir (arbidol) 1

control

prone positioning

miscellaneous

acetylcysteine

alpha lipoic acid 1

aviptadil

bevacizumab

bismuth

BLD-2660 (calpain inhibitor)

calcium channel blocker

camostat mesilate

continuous positive airway pressure (CPAP)

cytokine adsorption

diammonium glycyrrhizinate

dipyridamol

DPP-4 inhibitor

enoxaparin

kinin-kallikrein inhibitors

levamisole

metformin

natural killer (NK) cells

nicotin

nitric oxide (gas Inhalation or releasing solution)

ozonated autohemotherapy

pamrevlumab

proton pump inhibitors 3

PUL-042 inhalation solution

selinexor

statins

stem cells

tradipitant

tranilast

Latest studies

BACC Bay Tocilizumab Trial , 2020   NCT04356937 3 days ago

tocilizumab vs. placebo - COVID-19 severe or critically low risk of bias

  • inconclusive results for: death; mechanical ventilation or death; clinical improvement on ordinal scale; clinical worsening on ordinal scale

meta-analysis

CORIMUNO-19 , 2020   NCT04331808 4 days ago

tocilizumab vs. standard of care - COVID-19 mild to moderate some concern in risk of bias

  • inconclusive results for: death (day 28); WHO-CPS score greater than 5 at day 14; Mechanical Ventilation, or Death (day 14)

meta-analysis

RCT-TCZ-COVID-19 , 2020   NCT04346355 4 days ago

tocilizumab vs. standard of care - COVID-19 mild to moderate some concern in risk of bias

  • inconclusive results for: death before 30 days; clinical worsening 14 days

meta-analysis

SOLIDARITY (WHO study) HCQ , 2020   NCT04315948 9 days ago

hydroxychloroquine vs. standard of care - COVID 19 hospitalized some concern in risk of bias

  • inconclusive results for: 28 days death; death or initiation of ventilation

meta-analysis

SOLIDARITY (remdesivir) , 2020   NCT04315948 9 days ago

remdesevir vs. control - COVID 19 hospitalized some concern in risk of bias

  • inconclusive results for: in-hospital mortality; death or initiation of ventilation; initiation of ventilation

meta-analysis

SOLIDARITY (lopi/rito) , 2020   NCT04315948 9 days ago

lopinavir/ritonavir vs. control - COVID 19 hospitalized some concern in risk of bias

  • inconclusive results for: in-hospital death

meta-analysis

SOLIDARITY (interferon) , 2020   NCT04315948 9 days ago

interferon vs. control - COVID 19 hospitalized some concern in risk of bias

  • inconclusive results for: In-hospital deaths; death or initiation of ventilation

meta-analysis

hydroxychloroquine vs. placebo - COVID-19 prophylaxis low risk of bias

  • suggested 41 % decrease in any AE
  • inconclusive results for: PCR positive or probable Covid-19; Covid-19 compatible with symptoms; PCR confirmed Covid-19; gastrointestinal disorders

meta-analysis

hydroxychloroquine vs. placebo - COVID-19 prophylaxis low risk of bias

  • inconclusive results for: Covid-19 compatible with symptoms; PCR positive or probable Covid-19; PCR confirmed Covid-19; any AE; gastrointestinal disorders

meta-analysis

PATCH PreP (Abella) , 2020   NCT04329923 4 weeks ago

hydroxychloroquine vs. placebo - COVID-19 prophylaxis some concern in risk of bias

  • inconclusive results for: PCR confirmed infection rate

meta-analysis

Follow-us

This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.

   

- About - Our approach - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons